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equine penile squamous cell 
carcinoma: expression of biomarker 
proteins and EcPV2
callum Arthurs  1, Alejandro Suarez-Bonnet  2, claire Willis2, Boyu Xie1, natalie Machulla1, 
tim S. Mair3, Kevin cao1, Michael Millar4, christopher thrasivoulou5, Simon L. priestnall  2 & 
Aamir Ahmed1 ✉
equine penile squamous cell carcinoma (epScc) is a relatively common cutaneous neoplasm with 
a poor prognosis. in this study, we aimed to determine the protein expression and colocalisation 
of FRA1, c-Myc, Cyclin D1, and MMP7 in normal (NT), tumour (T), hyperplastic epidermis and/or 
squamous papilloma (Hyp/Pap), poorly-differentiated (PDSCC), or well-differentiated (WDSCC) EpSCC 
using a tissue array approach. further objectives were to correlate protein expression to (i) levels of 
inflammation, using a convolutional neural network (ii) equine papillomavirus 2 (EcPV2) infection, 
detected using PCR amplification. We found an increase in expression of FRA1 in EpSCC compared 
to NT samples. c-Myc expression was higher in Hyp/Pap and WDSCC but not PDSCC whereas MMP7 
was reduced in WDSCC compared with NT. There was a significant increase in the global intersection 
coefficient (GIC) of FRA1 with MMP7, c-Myc, and Cyclin D1 in EpSCC. Conversely, GIC for MMP7 with 
c-Myc was reduced in EpSCC tissue. Inflammation was positively associated with EcPV2 infection in 
both NT and EpSCC but not Hyp/Pap. Changes in protein expression could be correlated with EcPV2 
for Cyclin D1 and c-Myc. Our results evaluate novel biomarkers of EpSCC and a putative correlation 
between the expression of biomarkers, EcPV2 infection and inflammation.
Equine penile squamous cell carcinoma (EpSCC) is a cutaneous neoplasm with a poor prognosis that often results 
in euthanasia due to late presentation, treatment difficulties and deterioration. EpSCC are often seen with pre-
cancerous pink to yellow plaques and genital papillomas. The lesion is seen mostly at the end of the second and 
beginning of the third decade of life1. The term penile intraepithelial neoplasia (PIN) used in humans may also 
be applied to these lesions.
After sarcoids, squamous cell carcinomas are considered the most common equine neoplasm1–3. Around one 
tenth of all equine neoplasms are diagnosed in the penis, vulva and ocular adnexa4,5 of which EpSCC is the most 
common. Incidence rates of EpSCC, reported more in ponies compared to horses6, vary and no specific breed 
predilection has been ascertained6. The recorded incidence rates for EpSCCs are between 50–80% of all external 
genital neoplasms, however one report recorded that EpSCC made up around a fifth of all diagnosed equine 
cancers in a single UK laboratory over a 29-year period, with the incidence of cutaneous equine tumours also 
varying by region6.
The possible causes of EpSCC are suggested to be smegma accumulation, ultraviolet light overexposure, 
chronic irritation and balanoposthitis7. Chronic inflammation is a known risk factor for cancer development8. 
It is also thought that a majority of solid tumours are infiltrated with immune and inflammatory cells9. The link 
between human papilloma virus (HPV), cervical cancer10 and chronic inflammation is known8. There is evidence 
to suggest that equine cancers may be initiated, in part, by papillomavirus infection analogous to human cervi-
cal and penile cancer11. These suggest an inflammation7 and equine papillomavirus 2 (EcPV2) infection driven 
oncogenesis7,12, similar to the sexually-transmitted infection (STI) model proposed in human cervical cancer13.
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A 2007 study investigated the presence of EcPV1 in a selection of equine papilloma, aural plaque, sarcoid 
and normal tissue samples with results suggesting that >50% of cutaneous papilloma samples tested positive for 
EcPV1 but the virus was not found in the small number of genital samples that were tested14. In other studies7,15,16, 
EcPV2, a papillomavirus from a separate genus to EcPV117, has been suggested as an initiating factor for EpSCC. 
It has also been suggested that EpSCC may be more likely to develop in EcPV2 infected tissue because of raised 
levels of inflammation, which is associated with both tumorigenicity and papilloma virus infection7,12. However, 
it is difficult to separate cause from effect from these findings. The diagnostic and prognostic indicators rely on 
histopathological interpretation, whilst mechanisms of molecular carcinogenesis are not yet known.
We recently discovered that the activation of the Wnt pathway is an important feature of human penile squa-
mous cell carcinoma18. The Wnt network is a highly evolutionarily conserved signalling pathway, known to play 
a role in cell homeostasis, differentiation, proliferation, development and motility. The Wnt pathway, directly and 
indirectly, also promotes gene transcription of numerous targets, many of which are transcription factors19. An 
intersection of the links between the Wnt pathway, cancer and inflammation is to be found in bowel diseases. 
Mutations in the Wnt pathway are predominant in human colon cancer20 and there is also emerging evidence that 
the Wnt signalling network is involved in the modulation of the inflammatory response, as reviewed recently21.
In this study, we investigated if aberrations in human penile cancer related proteins, thought, generally, 
although not exclusively, to be under the transcriptional control of the Wnt signalling pathway in horses. Because 
EcPV2 and inflammation have also been predicted as a risk factor in the development of EpSCC, we also wished 
to test for changes in protein expression in relation to the presence of inflammation and EcPV2 expression. To 
investigate this notion, we selected four proteins associated with Wnt signalling and human penile squamous cell 
carcinoma: Matrix Metalloproteinase 7 (MMP7), Cyclin D1, c-Myc, and Fos-like antigen 1 (FRA1). FRA1 is a 
member of the Fos family of proteins, which also includes Fos B, c-Fos, and Fra222 and a target of transcription for 
the Wnt signalling pathway. The Fos proteins, along with proteins from the Jun family, make up the activator pro-
tein 1 (AP1) transcription factor23. There has been much interest in the role of aberrant expression of Fos proteins 
in multiple human cancers, including cancers of the liver, pancreas and ovaries24–27. We have previously shown 
the up-regulation of MMP7, Cyclin D1, c-Myc in human penile squamous cell carcinoma18.
In analysing cancer related proteins, putatively associated with the Wnt pathway, in EpSCC and their asso-
ciation with EcPV2 infection we may find dual benefit in creating an animal model of human disease as well as 
improving our understanding of an equine condition that causes significant morbidity. Using a cohort of EpSCC 
tissue, we conducted medium throughput protein staining and imaging and a quantitative approach previously 
established in our laboratory18,28–31 to investigate the hypothesis that viral-driven alterations in inflammation may 
play a role in EpSCC development.
Results
pathology. Histopathological evaluation of slides was used to define the cores as either Normal (NT), Hyp/
Pap, or EpSCC (Fig. 1), the degree of differentiation (poorly-differentiated EpSCC (PDSCC), or well-differen-
tiated EpSCC (WDSCC)) was also recorded for each tissue core. In addition, mitotic index (MI), a measure of 
cellular proliferation which describes the ratio of cells undergoing mitosis was also calculated (Table 1). In total, 
13 out of 34 cases were well-differentiated tumours, whilst 20 were poorly-differentiated; MI was positively cor-
related with malignancy (p = 0.04). In well-differentiated tumours, mean MI was 9 ± 7 whilst in poorly-differen-
tiated cases MI value was 23 ± 16 (mean ± SD).
Quantification of inflammatory cells in EpSCC. Inflammation was estimated by using three independ-
ent methods: 1. A convolutional neural network (CNN) 2. Visual scoring by expert pathologists (SLP and ASB) 
and 3. Staining for cluster of differentiation 3 (CD3) protein followed by unbiased quantification (see methods). 
A CNN was trained on a training dataset of inflammatory cell images (Fig. 2 and Supplementary Fig. 1), the 
resulting classifier is likely to identify cells based on the intensity of the nuclear chromatin staining with hae-
matoxylin and cell shape (roundedness). The trained CNN classifier was used to make predictions across each 
H&E stained tissue core on areas of pixels that contain an image of tissue, using a hue saturation value (HSV) 
threshold. The total number of positive predictions over total predictions was used as a measure of inflammation, 
per core (Fig. 2A–E; examples of H&E stained images, E – H; predictions from CNN analysis overlaid on the 
original, corresponding images). The cell types identified were predominantly lymphocytes and plasma cells, 
and the network rarely misclassified areas of tissue such as the dark regions (clumped chromatin) in the nuclei of 
non-inflammatory cells or keratinocyte nuclei. A significant difference in levels of CNN measured inflammation 
between NT and both Hyp/Pap (p < 0.05) and EpSCC (p < 0.001) (Fig. 2I) was also observed. A higher level of 
inflammation was also observed in tissue cores that were determined to be positive for EcPV2 (Fig. 2J; also see 
Supplementary Fig. 3 for a panel of H&E images). In EcPV2+ cases, levels of inflammation were significantly 
higher in both the NT and EpSCC cohorts (p < 0.001) (Fig. 2J).
Visual analysis and scoring by pathologists was also used to estimate inflammation and correlate to CNN anal-
ysis, described above. Each tissue core was assigned a score for staining (0 = no inflammation, absent (0%); 1= 
mild (>0% to <5%); 2 = moderate (≥5% to <40%) 3 = marked inflammation >40%) by the pathologists. It was 
noted in this analysis that inflammatory cells were most often located in the stroma/propria immediately adjacent 
to the tumour. This can be seen in the example images in Fig. 2A–F and Supplementary Fig. 2A-F. Furthermore, 
there was a significant increase in EpSCC versus NT inflammation (p < 0.05) and an increase in EcPV2+ versus 
EcPV2− inflammation score for both NT and EpSCC (p < 0.05).
CD3 staining was used as another measure of inflammation for correlation and comparison with CNN anal-
ysis. Serial sections of tissue arrays were stained using a DAB immunohistochemistry protocol with a CD3 anti-
body followed by imaging and automated quantification of DAB stain. The results showed that CD3 expression 
in EpSCC cores was significantly higher than NT cores (Supplementary Fig. 2G) and a significant increase was 
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also observed in the inflammation in EcPV2+ cores for the NT and EpSCC samples compared to EcPV2− cores 
(Supplementary Fig. 2H).
The analysis by pathologists and the quantification of CD3 staining correlated well with observations obtained 
using the CNN method demonstrating an increased inflammation in EpSCC compared with NT (p < 0.05) and 
an increase in EcPV2+ versus EcPV2− inflammation score for both NT and EpSCC for all three methods of 
quantification (Supplementary Fig. 2G,H). This was further confirmed when concordance between the CNN 
(Supplementary Fig. 2I) and CD3 (Supplementary Fig. 2J) inflammation quantification versus pathologist scoring 
(CNN (bias; SD of bias: 0.95; 0.82), CD3 (bias; SD of bias: 0.64; 0.71)) using the Bland-Altman test.
protein expression in epScc. DAB label was detected for all four proteins in both NT and EpSCC equine 
tissue (Fig. 3, Supplementary Fig. 4). The protein expression of MMP7, c-Myc, and FRA1 was altered in WDSCC 
compared to NT (Fig. 4). In experimental controls, where tissue samples were incubated only with the secondary 
antibody and the primary antibody was omitted, no DAB signal was observed (see methods). MMP7 expression 
was significantly reduced in both Hyp/Pap (p < 0.05) and WDSCC (p < 0.01) tissue when compared to normal 
tissue. c-Myc expression showed an increase in both Hyp/Pap and WDSCC compared to NT (p = 0.0001). A sig-
nificant difference in c-Myc expression was also observed between PDSCC and WDSCC (p < 0.005, Fig. 4). FRA1 
protein expression showed an increase in all pathologies compared to NT (p < 0.0001).
ROC curves were constructed to test the sensitivity and specificity of protein expression as a predictor of 
EpSCC. The ROC curve for FRA1 revealed a moderate ability to correctly classify tumour or tumour adjacent 
tissue cores with an AUC of 0.85 (Youden index: sensitivity = 72.34, specificity = 88.57, criterion value > 74.10) 
(Fig. 5).
Figure 1. Histological grading of specimens. Representative, 1 mm diameter tissue core images of normal, 
squamous papilloma and squamous cell carcinoma. Tissue arrays were constructed containing tumour and 
tumour adjacent samples. The H&E section of this tissue array was used for classification of the disease by two 
expert veterinary pathologists. Pathological features are noted next to the tissue cores.
Tumour Type (n)
Mitotic Index
SignificanceMean Range
EpSCC (34) 18 2–66
p = 0.04*
pP (11) 9 1–30
Well-differentiated pSCC (14) 9 2–22
p < 0.001***
Poorly-differentiated pSCC (20) 23 3–66
Table 1. Mitotic index for tumour type and differentiation. Number of samples (n) is recorded for each tumour 
and differentiation type. Mitotic index, defined as the total number of mitotic figures counted in ten x400 fields 
at 2.37mm2, was calculated by expert veterinary pathologists from H&E stained tissue array images. Mitotic 
index was positively correlated to malignancy (*p < 0.05).
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EcPV2 viral nucleic acid specific PCR. Of the 43 formalin-fixed paraffin-embedded (FFPE) EpSCC tissue 
samples collected, 35 samples yielded DNA of acceptable quality for PCR using EcPV2 primers (Supplementary 
Table 1). Of these 35 samples tested, 13 showed a PCR product (224 bp) corresponding to the predicted size for 
the primers representing a section of the E1 region EcPV2 (Supplementary Fig. 5).
Protein Expression in EcPV2 positive EpSCC. From a sample set of 166 tissue cores we identified 47 
samples that were EcPV2 + (EpSCC n = 23, NT n = 14) and 87 samples which were EcPV2− (EpSCC n = 60, NT 
n = 17; a panel of H&E images is also provided in Supplementary Fig. 3). Comparative analysis was conducted in 
EcPV2+ vs EcPV2−, between NT and EpSCC samples). There was a significant (p < 0.05) change in the expres-
sion of Cyclin D1 and c-Myc in tissue samples that were EcPV2 + (Fig. 6). The protein expression of Cyclin D1 
was reduced in EcPV2 tissue samples in both the NT and EpSCC cohorts. The expression of c-Myc was reduced 
in EpSCC EcPV2+ samples only (Fig. 6).
Quantitative colocalisation of two proteins. Tissue array slides stained to detect multiple proteins were 
analysed using deconvolved, confocal images, to measure protein co-localisation by calculating the global inter-
section coefficient (GIC) in NT and diseased tissue cores (Fig. 7, Supplementary Figs. 6, 7). There was a significant 
Figure 2. Quantification of inflammatory cells on H&E stained tissue cores. A CNN, consisting of two 
convolution layers and a fully connected layer, was trained on a dataset of 1200 images (11 × 11 pixels) of 
inflammatory cells and 1897 images of non-inflammatory areas of tissue. Predictions were made on a 11 × 11 pixel 
regions of tissue (A–D; H&E stained tissue core image, (E–H); H&E stained tissue core image with predictions 
overlaid). Green squares represent non-inflammatory predictions and the larger red squares represent the centroid 
of an image that has been predicted as inflammation (E-H). The final value for inflammation was calculated as 
a fraction of predicted inflammatory areas over total areas of tissue for each core (EpSCC EcPV2 + n = 23, NT 
EcPV2 + n = 14, EpSCC EcPV2− n = 60, NT EcPV2− n = 17). Box plots (I, J) were constructed in GraphPad 
Prism to compare levels of CNN calculated inflammation in different pathologies (I) and EcPV2 infection status 
(J) (Mann Whitney U, ***p < 0.0001, **p < 0.001, *p < 0.05).
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change in GIC for FRA1/Cyclin D1, FRA1/MMP7, and FRA1/c-Myc (p < 0.0001) and MMP7/c-Myc (p < 0.005) 
in EpSCC tissue cores compared with NT cores.
Discussion
We have previously found increased expression of the Wnt signalling targets Cyclin D1, MMP7 and c-Myc in 
human penile squamous cell carcinoma18. Here, we have analysed the expression of these proteins and FRA1, 
another known target of Wnt signal activation32, to further investigate this phenomenon in equine tissue. 
Although each biomarker was chosen for its known association with Wnt signalling with respect to four pathol-
ogies (NT, Hyp/Pap, PDSCC and WDSCC), the transcription of these genes is not exclusively under the control 
of Wnt/beta catenin transcription factor co-activator33,34. We showed that there were significant deviations from 
normal expression in c-Myc, MMP7, and FRA1 that may be further investigated as use as a biomarker of disease.
Cyclin D1. Cyclin D1 belongs to the cyclin family and assists in regulation of cell migration and cell cycle 
progression by controlling G1/S phase transition and has a role in regulating cell proliferation and differentiation 
by binding to nucleolar receptors. Evidence implicates Cyclin D1 in the invasiveness and metastatic capability of 
urinary bladder tumours35,36.
MMP7. MMP7 is part of the MMP family of peptidases, who have a major role in the breakdown of 
extra-cellular matrix in normal physiological processes, embryonic development, and reproduction and tissue 
remodelling. It is implicated in the aggressiveness and metastatic potential of bladder cancer37–39.
c-Myc. c-Myc is a transcription factor that receives direct signals from Wnt as well as other pathways, being 
involved in cell proliferation, apoptosis and differentiation. It is implicated in bladder cancer, being overexpressed 
and seen as a potential target for chemotherapeutics40–42.
FRA1. FRA1 plays important roles in various biological processes, including inflammation, transformation, 
proliferation and metastasis43. It is a direct target of the Wnt signalling pathway44 and the Interleukin (IL) signal-
ling pathway IL-17RA45. FRA1 is implicated in the development and upregulation of various human malignancies 
including lung, brain, breast and bladder43,46–48.
Figure 3. Tissue array cores, staining, imaging and analysis. Representative examples of H&E stain, single 
label DAB staining and grey scale converted images tissue cores are shown. Tissue arrays containing tumour 
and tumour adjacent EpSCC tissue were constructed using a Beechers manual tissue arrayer. Sister tissue array 
sections (4 µm) were stained with H&E (top row) or labelled (DAB) with either MMP7, FRA1, c-Myc, or Cyclin 
D1 (middle row) for quantitative protein analysis using a colour thresholding method in ImageJ software. 
The number of pixels within the thresholded image (binary mask, bottom row) is then counted and divided 
by the total amount of pixels that represent tissue in each 1 mm core. Analysis of tissue arrays, from which 
these examples are shown, were used for quantification and statistical comparisons are then made between the 
amount of FRA1 stain in tumour and tumour adjacent tissue using a Mann Whitney U test.
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Additionally, FRA1 is implicated in human research to regulate inflammatory processes, leading to disease 
such as Rheumatoid and osteoarthritis49. Considering the emerging importance of FRA1 in cancers, we asked the 
question, is FRA1 expression altered in EpSCC tissue?
Figure 4. Protein expression in NT, Hyp/Pap PDSCC and WDSCC tissue cores. Tissue arrays were stained 
for MMP7, c-Myc, FRA1 and Cyclin D1. Tissue core images were thresholded for the amount of stain per 
amount of tissue for each tissue core (AFperAMT). Mountain plots (left) were constructed to show the protein 
expression for each tissue core with EpSCC tissue cores shown by red bars and normal tissue cores shown by 
green bars. A box plot of the AFperAMT in tumour and tumour adjacent cores was constructed to illustrate 
the change in expression in tumour tissue (right). Significance is represented by a * (Mann Whitney U, 
****p < 0.0001, ***p < 0.001, **p < 0.005, *p < 0.05).
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FRA1 is a downstream target of the Wnt/beta-catenin signalling pathway, which is implicated in the develop-
ment of several malignancies43. We discovered that a number of Wnt targets of transcriptions were upregulated 
in human penile squamous cell carcinomas, suggesting a role for this pathway in penile carcinoma18. Wnt as 
a core pathogenetic driver of squamous cell carcinoma in humans has also been observed in other tissues50,51. 
Additionally, aberrant expression of FRA1 through Wnt activation has also been shown in glioma cells, indicating 
a linkage43.
Previous studies have indicated that EcPV2, a non-enveloped DNA virus, is associated with the presence of 
EpSCC. Here, we have directly corroborated this observation by screening 36 EpSCC samples for the presence of 
the viral infection, finding its presence in 13 cases.
Pathological observations showing inflammation accompanying a significant number of EpSCC samples is in 
keeping with other studies7,12, an observation that is also seen in human penile squamous cell carcinoma52. This 
may support a model of inflammation as a possible aetiological factor for EpSCC, with infection precipitating the 
inciting inflammatory processes. If this is the case, EcPV2 is an indirect precipitant of EpSCC and therefore the 
increased expression of FRA1 could be explained by its role in the immune response. FRA1 overexpression in 
transgenic mice models has been shown to have increased inflammatory cell infiltration in the liver49.
Inflammation, EcPV2 and EpSCC. The association between chronic inflammation and oncogenesis 
has been a subject of intensive discussion and research for some time53. Dvorak54 suggested that tumours are 
wounds that don’t heal. The relationship between papilloma virus infection and inflammation is also well doc-
umented55. There is evidence, both in human and horse, associating papillomavirus infection with squamous 
cell carcinomas of the penis7,15,56. The relationship between infection and dysplasia (a pre-malignant change) is 
well-characterised in the case of human cervical cancer, where HPV is found in over 99% of cervical cancers13. 
Integration of viral DNA into local tissue disrupts cellular processes that may lead to malignancy. Similar vari-
ations in HPV association are seen in equine cancers where rates vary between 45 and 100%7,15 suggesting that 
Figure 5. Receiver operating characteristics (ROC) curves. The AFperAMT for each tissue core was calculated 
using ImageJ software. AFperAMT for each core was then indexed according to the histopathological 
diagnosis provided independently by two veterinary pathologists evaluating a serial section of the TA stained 
with H&E. ROC curves were constructed using MedCalc software. Area under the curve (AUC) values and 
optimal sensitivity and specificity calculated using the Youden index (considered a measure of the best putative 
performance of a dichotomous diagnostic test) are as follows: FRA1; sensitivity = 72.34, specificity = 88.57, 
Area under the curve (AUC) = 0.854, criterion value > 74.1. c-Myc; sensitivity = 41.49, specificity = 91.43, 
AUC = 0.637, criterion value > 62.5. Cyclin D1; sensitivity = 61.70, specificity = 53.29, AUC = 0.559, criterion 
value > 61.5. MMP7; sensitivity = 92.56, specificity = 37.14, AUC = 0.627, criterion value <74.1.
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there are other potential causes of mucosal squamous cell carcinomas in the horse, with UV-radiation, smegma 
accumulation and breed factors have been suggested4,57. We have used a CNN method of inflammatory quantifi-
cation as a fast and cost-effective method of comparing inflammatory cell levels in H&E images, complimenting 
immunohistochemical and scoring methods employed by pathologists. The comparative methods show a good 
level of concordance (Supplementary Fig. 2).
Cluster of differentiation 3 (CD3) is a protein complex composed of epsilon, gamma, delta and zeta polypep-
tide chains. The CD3 complex binds to T cell receptors (TCR) and is considered a T cell marker58. It is known 
that CD3 expression is associated with inflammation. For example, the number of CD3 + cells was shown to be 
increased in patients with rheumatoid arthritis59. CD3 has thus been used as a marker for inflammation in tissues 
for many years60. CD3 expression in equine tissue was first described by Blanchard-Channell61 in mononuclear 
leucocytes and lymphoid tissue. Both the scoring method used by pathologists and CD3 quantification support 
the idea that the CNN methodology described here may be used to detect inflammation levels between tissue 
samples.
Utilising the CNN methodology, we found a positive correlation between inflammation and EcPV2 and 
EpSCC. There was an increase in inflammation in both NT EcPV2+ and EpSCC EcPV2+ samples compared 
with EcPV2− samples of the same cohort. We can perhaps, speculate that immune response to EcPV2 is a factor 
contributing to EpSCC progression. The CNN approach could be applied to other human (e.g. prostate28,30) and 
animal cancers29.
Materials and Methods
Sample selection and tissue array construction. Only FFPE tissue from pathology archives was used 
in this research. The tissue samples were collected for diagnostic and/or treatment purposes. Archival tissue col-
lection for use in research were subject to institutional ethical review. Ethical approval for the use of equine tissue 
was granted by the Clinical Research Ethical Review Board (CRERB) of the Royal Veterinary College, University 
of London. All methods were performed in accordance with the relevant guidelines and regulations. Forty-three 
FFPE tissue samples of histologically diagnosed EpSCC were obtained from the pathology archives of the Royal 
Veterinary College and University of Bristol, UK. Samples originated as either incisional or excisional biopsies 
taken for diagnostic purposes for the animal (mean age 19, range 8–33 years) (Supplementary Table 1). Clinical 
data, where present (histological diagnosis, treatment and outcome) were collated with sample labels coded to 
maintain the blind experimental design. Samples were sectioned, stained with haematoxylin and eosin (H&E), 
and independently classified by two veterinary pathologists (SLP and ASB) for both disease process and differen-
tiation, defined here as well-differentiated and poorly-differentiated. Areas of EpSCC (n = 34), tumour-adjacent 
control (n = 23), and Penile Papilloma (pP) (n = 11) were marked on the tissue block for tissue array construction.
A sample size calculation was made incorporating parameters from previously described studies18,28–30; the 
minimum tumour and control group sizes were 21 and 7 respectively to ensure adequate statistical power to 
detect differential expression of protein signal. Tissue arrays were constructed using a Beecher Instruments 
Microarrayer (MTA-1 tissue arrayer, Beechers Instruments, Sun Prairie, WI, USA). Tissue samples were cored 
from the areas marked by the pathologists. Tissue arrays (TA) were constructed with paired control (defined 
Figure 6. Protein expression in EpSCC and NT tissue cores identified EcPV2 positive or negative. Protein 
expression for Cyclin D1 and c-Myc was evaluated using a TA technique. Genomic DNA was isolated from 
EpSCC tissue samples and screened for the E1 region of the EcPV2 viral DNA. Tissue array cores were labelled 
according to their virus infection and expression levels were compared for tumour (EpSCC) and tumour 
adjacent (NT) tissue cores. Samples that were identified as either hyperplastic or papilloma (Hyp/Pap) were not 
included in this analysis. Tests of significance are labelled with a bracket (*p < 0.05). Other proteins that were 
tested, FRA1 and MMP7, showed no significant difference in expression correlated with virus presence.
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here as tumour-adjacent) and tumour samples on the same array (where applicable). Tumour tissue samples 
were repeated in triplicate and tumour adjacent specimens in duplicate. A total of five TA paraffin blocks were 
constructed with 1 mm cores at 3 mm intervals. Random core positioning ensured replicated samples were dis-
tributed evenly across the array to control for staining procedures. A (4 µm) section from each TA was stained 
with H&E and again each core was histopathologically examined and assigned a classification of either: NT, Hyp/
Pap, PDSCC, or WDSCC.
Figure 7. Colocalisation of FRA1, Cyclin D1, c-Myc, and MMP7. TA slides, labelled for Cyclin D1, MMP7, 
c-Myc, and FRA1 with FITC (488/517 nm, Blue), Cy3 (514/565 nm, Yellow), Cy5 (633/671 nm, Green), and 
Coumarin (405/470 nm, Red), respectively, were imaged at both low (10×, A,B) and high (40x with a 6x zoom, 
C and D) using a Leica TCS SP8 confocal microscope (n = 12, 6 EpSCC and 6 NT). High magnification, z stack, 
images (0.17 µm step size) were first deconvolved using Huygens software. The global intersection coefficient 
(GIC) was calculated between each channel as a measure of colocalisation of two proteins. Box plots and tests of 
significance were carried out using GraphPad Prism (Mann Whitney U, ****p < 0.0001, **p < 0.005).
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immunohistochemistry. The antibodies, Cyclin D1 (sc-718 Santa Cruz), MMP7 (ab4044 Abcam), c-Myc 
(NCL-cmyc Novacastra/Leica), and FRA1 (ab117951 Abcam) were optimised for pH dependence, antigen 
retrieval, and concentration. Following optimisation, single label, 3,3-diaminobenzidine-horse radish peroxidase 
(DAB) staining was performed for each protein (Supplementary Fig. 4) at the following dilutions 1:500, 1:250, 
1:250, 1:1000 respectively.
All tissue array slides were stained with the Bond Max automated staining system (Leica Biosystems, Milton 
Keynes, UK) in a single experiment to reduce inter-slide variations in staining. Control staining was carried out 
where no primary antibody was used (Supplementary Fig. 8). A multi-label stain was performed with Cyclin 
D1, MMP7, c-Myc, and FRA1 which, after binding to the respective Horse Radish Peroxidase secondary anti-
body, were visualised following the principle of Toth and Mazey using the following fluorescent tyramides; FITC 
(488/517 nm), Cy3 (514/565 nm), Cy5 (633/671 nm), and Coumarin (405/470 nm), respectively.
DAB stain Imaging and analysis. Single label DAB stained slides were imaged at 40x magnification using 
a Nanozoomer slide scanner (Hammamatsu Photonics UK Ltd, Welwyn Garden City, UK) and an image of each 
individual tissue core was exported and indexed according to its configuration on the TA (Supplementary Fig. 4). 
Images were analysed using ImageJ software62 and algorithms developed in our laboratory18,28. Areas containing 
the DAB stain (brown) were segmented on hue, saturation, and brightness. Areas containing tissue were iden-
tified on a duplicate image by conversion to 8-bit and application of a threshold to only measure pixels that are 
not the same intensity as the background. Thresholds were optimised on a training set of images (n = 20 for each 
antibody) before being applied to the whole image set for standardization of quantitation. A macro was compiled 
for unbiased quantitation to measure both the amount of DAB signal and the amount of tissue. Areas of folded 
tissue were excluded from analysis. Results are expressed as the amount of signal divided by the amount (AMT) 
of tissue and fitted to a probit regression (Area Fraction, AFperAMT). Mountain plots and Box plots illustrating 
changes in protein expression were created in GraphPad Prism. Tests of statistical significance between tumour 
and tumour adjacent tissue cores were conducted using a Mann Whitney U test (Medcalc software). A receiver 
operating curve (ROC) curve was constructed to test the ability of the quantified protein labels to correctly clas-
sify between tumour and tumour adjacent tissue cores.
EcPV2 PCR and Amplicon Sequencing. Genomic DNA was isolated from FFPE equine penile tissue using 
a QIAamp DNA FFPE Tissue Kit (Qiagen, Manchester, UK). Primers for the E1 region EcPV2 (Genbank sequence 
EU503122.1) were used which have previously been used to show the presence of the viral DNA in equine penile 
tissue (EcPV2 Forward: ATTACCGCAGAGCGGAGATG, EcPV2 Reverse: GCTGGACTTGCCAGTGTTTG)7. 
PCR reactions containing Taq PCR Master Mix (Qiagen, Cat no: 201445) 20 µL, 0.1 µM EcPV2 forward and 
reverse primers, and 5 µL template were amplified at 94 °C for 3 minutes and 30 cycles of 94 °C for 1 minute, 57 °C 
for 1 minute, and 72 °C for 1 minute, followed by 72 °C for 5 minutes. DNA extraction from amplicons was carried 
out with a QIAquick Gel Extraction Kit (Qiagen, Manchester, UK). Amplicon sequencing was undertaken by 
Geneservice Source BioScience PLC (Nottingham, United Kingdom).
Quantification of inflammatory cells in EpSCC. To test for any association of tumorigenicity and 
EcPV2 infection with inflammation, areas within the tissue cores with inflammatory cell infiltration were 
assessed (SP and ASB). These areas were used to train a convolutional neural network (CNN); the CNN was 
implemented using Keras63 and Tensorflow64 with an architecture consisting of two convolution layers, a fully 
connected layer and an output layer. The resulting CNN was trained on a NVidia 2080ti GPU. Training data-
sets were constructed using 15% of the total number of H&E tissue cores (n = 149). 11 × 11 pixel images of 
inflammatory cells (n = 1200) and non-inflammatory areas of tissue (n = 1897) were manually curated and used 
for CNN training. The non-inflammatory areas category also included areas of out of focus and fragmented 
tissue that are likely to cause the CNN to misclassify an input image65. Predictions were then made on the entire 
dataset by first pre-processing whole core images to identify areas of tissue, using a colour threshold, and then 
iteratively making predictions on 11 × 11 pixel regions of tissue. The final value of inflammation was calculated 
as a fraction of inflammatory areas over non-inflammatory areas for the entire tissue core. Two methods were 
used to validate the CNN method of quantification. Firstly, H&E-stained images of each core were examined by 
two board-certified veterinary pathologists (SLP and ASB) and a consensus of total histological inflammatory 
score was assigned for each tissue based on the percentage of inflamed surface area in the core66 as follows: 0 = 
absent (0%); 1 = mild (>0% to <5%); 2 = moderate (≥5% to <40%); 3 = marked (≥40%). All inflammatory 
cells (lymphocytes, plasma cells and neutrophils) were assessed equally. Secondly, all tissue arrays were stained 
for CD3 (Leica Biosystems: CD3–565-L-CE), a T cell marker67 using quantitative immunohistochemistry (see 
above). DAB signal for CD3 staining was quantified independently for each tissue core using a quantitative meas-
ure to determine the fraction of stained tissue. Comparisons were made between the CNN method, analysis by 
pathologists, and levels of CD3 staining (expressed as mean ± SD) and Mann Whitney U test comparisons of sig-
nificance. Bland-Altman tests were also used to assess concordance between CNN analysis and comparison with 
scoring by pathologists and CD3 expression using quantitative immunohistochemistry. To do this comparison, 
CD3 and CNN quantification data was first scaled using the difference of the mean value, to fit in the pathologist 
score range. Bland-Altman was calculated using GraphPad Prism and plotted as (A –B) versus the mean of A and 
B, where method A is the scoring of inflammation by pathologist and method B is CD3 or CNN inflammation 
quantification, respectively.
Quantitative colocalisation. Multi-labelled tissue slides were imaged using a Leica SP8 confocal micro-
scope with a 40 × 1.4 NA objective and a 6x zoom was applied during image acquisition (equivalent to 4 times 
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over sampling to satisfy Nyquist criteria for deconvolution). Five Z-stack images with a z-step size of 0.17 µm 
(~ 20–28 z-sections per sample area) were taken from each tissue core (n = 12, 6 EpSCC and 6 NT). Images 
were deconvolved using Huygens software (Scientific Volume Imaging) and the global intersection coefficient 
(GIC) was calculated for each pair of channels in the 4-channel image. Representative images are shown in 
Supplementary Figs 6,7. The Mann Whitney U test was used for significance tests between EpSCC and NT tissue 
cores.
Data availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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